CD19 and lymphoma: Alternatively, transgenic mouse models can also permit the study of toxicity in an immunocompetent setting, such as the model used by Pennell et al. in which mice engineered to express human-CD19 and engrafted with a transgenic human-CD19-expressing lymphoma were treated with human-CD19 specific murine CAR T-cells to study toxicity mechanisms [189].